ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development

– Renowned physician-scientist brings deep expertise in clinical development and inhaled drug delivery to ReCode as lead programs for primary ciliary dyskinesia and cystic fibrosis enter clinical trials –

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development. Dr. Matthews will oversee clinical development planning and strategy.

“We are delighted to welcome Dr. Matthews to build and lead our clinical team,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics. “As a pulmonary and immunology drug developer with extensive experience in human genetics and inhaled drug delivery, Dr. Matthews brings a unique perspective at a formative stage of our development. I look forward to working with him as we continue to advance our pipeline of next generation precision genetic medicines for people affected by rare diseases.”

Dr. Matthews brings over twenty years of proven leadership in clinical trial design and drug development, and extensive patient care experience. He has significant expertise in rare pulmonary diseases and larger respiratory indications and was most recently at 23andMe, where he led their rare disease therapeutic strategy and provided leadership for drug development programs aimed at discovering novel genetic targets.

“With its selective organ targeting (SORT) lipid nanoparticle (LNP) technology, ReCode is pioneering a novel approach to solving one of the most significant challenges in the delivery of genetic medicines for rare diseases - an area I am incredibly passionate about,” said Dr. Matthews. “I look forward to playing a pivotal role in advancing ReCode’s lead candidates for primary ciliary dyskinesia and cystic fibrosis into the clinic this year, and ultimately, building a clinical pipeline aimed at unlocking the full potential of genetic medicines.”

Prior to 23andMe, Dr. Matthews served as vice president of clinical development at Aimmune Therapeutics supporting both late and early-stage programs. He spent the previous ten years at Genentech, a subsidiary of Roche, in leadership roles including senior group medical director. Before Genentech, Dr. Matthews held positions of increasing responsibility at Novartis Pharmaceuticals and was a clinical scientist in the department of early development for respiratory and inflammation products at GlaxoSmithKline, where he worked on a novel inhaled steroid among other molecules.

Dr. Matthews trained in pulmonary medicine at the Royal Brompton Hospital and the Lane Fox Respiratory Unit, St Thomas’ Hospital, London. He earned his Ph.D. in respiratory clinical pharmacology from Imperial College London. He is a member of the Unbiased BIOmarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) program and serves as executive director of RASP-UK, a large-scale research project that aims to target treatments effectively in patients with severe asthma.

About ReCode Therapeutics

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of messenger RNA (mRNA) and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. In 2022, ReCode was named among Fierce Biotech’s “Fierce 15” as one of the most promising early-stage biotechnology companies in the industry and was described by Nature as one of the “Seven Technologies to Watch in 2022” for its SORT LNP platform. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and on LinkedIn.

Investor Contact:
Sarah McCabe
Stern IR
Sarah.McCabe@sternir.com
IR@recodetx.com

Media Contact:
Tara Cooper
The Grace Communication Group
tara@gracegroup.us
650-303-7306